Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 133.96
ARWR's Cash to Debt is ranked higher than
52% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ARWR: 133.96 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s 10-Year Cash to Debt Range
Min: 0  Med: 14.97 Max: No Debt
Current: 133.96
Equity to Asset 0.89
ARWR's Equity to Asset is ranked higher than
80% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARWR: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s 10-Year Equity to Asset Range
Min: -39.56  Med: 0.73 Max: 0.95
Current: 0.89
-39.56
0.95
F-Score: 3
Z-Score: 8.87
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -29637.62
ARWR's Operating margin (%) is ranked lower than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ARWR: -29637.62 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s 10-Year Operating margin (%) Range
Min: -70800  Med: -2154.76 Max: -40
Current: -29637.62
-70800
-40
Net-margin (%) -28157.76
ARWR's Net-margin (%) is ranked lower than
96% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ARWR: -28157.76 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s 10-Year Net-margin (%) Range
Min: -33502.86  Med: -1678.24 Max: 1602.7
Current: -28157.76
-33502.86
1602.7
ROE (%) -51.07
ARWR's ROE (%) is ranked lower than
64% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ARWR: -51.07 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s 10-Year ROE (%) Range
Min: -225.02  Med: -83.06 Max: -28.66
Current: -51.07
-225.02
-28.66
ROA (%) -47.05
ARWR's ROA (%) is ranked lower than
67% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ARWR: -47.05 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s 10-Year ROA (%) Range
Min: -447.27  Med: -92.98 Max: 705.95
Current: -47.05
-447.27
705.95
ROC (Joel Greenblatt) (%) -2352.32
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ARWR: -2352.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11843.37  Med: -857.10 Max: -28.57
Current: -2352.32
-11843.37
-28.57
Revenue Growth (3Y)(%) -100.00
ARWR's Revenue Growth (3Y)(%) is ranked lower than
91% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARWR: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARWR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -52.50 Max: 63.5
Current: -100
0
63.5
EBITDA Growth (3Y)(%) -5.80
ARWR's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ARWR: -5.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56.3  Med: -24.90 Max: 190.5
Current: -5.8
-56.3
190.5
EPS Growth (3Y)(%) 1.90
ARWR's EPS Growth (3Y)(%) is ranked higher than
62% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ARWR: 1.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.1  Med: -20.60 Max: 162.1
Current: 1.9
-75.1
162.1
» ARWR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ARWR Guru Trades in

Q4 2013

ARWR Guru Trades in Q4 2013

Steven Cohen 1,500,000 sh (New)
Jim Simons 54,400 sh (New)
Steven Cohen 1,883,050 sh (New)
Steven Cohen 2,000,000 sh (+33.33%)
» More
Q1 2014

ARWR Guru Trades in Q1 2014

George Soros 44,200 sh (New)
Steven Cohen 2,740,000 sh (+82.67%)
Jim Simons Sold Out
» More
Q2 2014

ARWR Guru Trades in Q2 2014

Steven Cohen 3,225,000 sh (+115.00%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.47
ARWR's P/B is ranked higher than
74% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARWR: 2.47 )
Ranked among companies with meaningful P/B only.
ARWR' s 10-Year P/B Range
Min: 1.45  Med: 5.76 Max: 75.56
Current: 2.47
1.45
75.56
P/S 1079.46
ARWR's P/S is ranked lower than
180% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ARWR: 1079.46 )
Ranked among companies with meaningful P/S only.
ARWR' s 10-Year P/S Range
Min: 0  Med: 152.10 Max: 2468
Current: 1079.46
0
2468
EV-to-EBIT -2.67
ARWR's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ARWR: -2.67 )
Ranked among companies with meaningful EV-to-EBIT only.
ARWR' s 10-Year EV-to-EBIT Range
Min: -49.1  Med: -5.35 Max: -0.3
Current: -2.67
-49.1
-0.3
Current Ratio 9.10
ARWR's Current Ratio is ranked higher than
71% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ARWR: 9.10 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s 10-Year Current Ratio Range
Min: 0.01  Med: 3.05 Max: 302.61
Current: 9.1
0.01
302.61
Quick Ratio 9.10
ARWR's Quick Ratio is ranked higher than
72% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ARWR: 9.10 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s 10-Year Quick Ratio Range
Min: 0.01  Med: 4.49 Max: 302.61
Current: 9.1
0.01
302.61
Days Sales Outstanding 152.99
ARWR's Days Sales Outstanding is ranked lower than
85% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. ARWR: 152.99 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARWR' s 10-Year Days Sales Outstanding Range
Min: 1.12  Med: 42.98 Max: 1982.84
Current: 152.99
1.12
1982.84

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.63
ARWR's Price/Net Cash is ranked higher than
77% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ARWR: 3.63 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s 10-Year Price/Net Cash Range
Min: 0.05  Med: 7.55 Max: 103.64
Current: 3.63
0.05
103.64
Price/Net Current Asset Value 3.51
ARWR's Price/Net Current Asset Value is ranked higher than
77% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ARWR: 3.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s 10-Year Price/Net Current Asset Value Range
Min: 0.04  Med: 7.56 Max: 70.89
Current: 3.51
0.04
70.89
Price/Tangible Book 3.02
ARWR's Price/Tangible Book is ranked higher than
72% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ARWR: 3.02 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s 10-Year Price/Tangible Book Range
Min: 0.04  Med: 6.81 Max: 54.5
Current: 3.02
0.04
54.5
Earnings Yield (Greenblatt) (%) -37.26
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ARWR: -37.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -41.1  Med: 0.00 Max: 0
Current: -37.26
-41.1
0

Analyst Estimate

Sep15
EPS($) -1.41
EPS without NRI($) -1.41

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in 1989, and was reincorporated in Delaware in 2000. It is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. The product include ARC-520, Adipotide, CRLX-101, Tubulin Inhibitor.The drug products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the "FDCA"), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Reports Third Quarter Fiscal 2009 Financial Results Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Arrowhead Research reports 3Q loss Aug 04 2015
Arrowhead Research reports 3Q loss Aug 04 2015
5:03 pm Arrowhead Research reports Q2 results. Aug 04 2015
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2015
Arrowhead Reports Fiscal 2015 Third Quarter Financial Results Aug 04 2015
Q3 2015 Arrowhead Research Corp Earnings Release - After Market Close Aug 04 2015
Biotech Sector Review Aug 04 2015
Arrowhead to Report Fiscal 2015 Third Quarter Financial Results Jul 28 2015
Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand Jul 08 2015
Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand Jul 08 2015
Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand Jul 08 2015
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency Jul 02 2015
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency Jul 02 2015
Can Hepatitis B Be A Blockbuster Bug? Jul 01 2015
Edited Transcript of ARWR earnings conference call or presentation 11-May-15 8:30pm GMT Jun 19 2015
Arrowhead Research (ARWR) Stock Gains as Germany Clears Further HBV Tests Jun 17 2015
Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B... Jun 17 2015
Arrowhead Research Corporation receive ‘orphan’ status for drug to prevent progression of liver... Jun 15 2015
Arrowhead Receives Orphan Drug Designation for ARC-AAT Jun 10 2015
Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK